Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 192

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 192
---
 safety gains for patients treated with ADCs.

- 129 -

Source:
Weisser et al. Nat Commun. 2023;14(1):1394.

There are several biparatopic molecules that provide precedent for demonstrating increased therapeutic
benefit compared to their single epitope counterparts. For example, zanidatamab, a biparatopic HER2 Ab (Jazz Pharmaceuticals) binds the same epitopes as trastuzumab (Herceptin) and pertuzumab (Perjeta). Zanidatamab demonstrated approximately 20%
increase in ORR compared to monoparatopic trastuzumab while maintaining a tolerable safety profile.

Our biparatopic SEZ6 ADC, biSEZ6-CPT113, is the only
biparatopic ADC in development for small cell lung cancer, and shows potential to outperform the available treatment approaches and the single epitope ADCs in development.

Preclinical models suggest the biSEZ6 antibody shows superior binding and internalization compared to single epitope SEZ6 antibody counterparts, including the
antibody used in ABBV-706, with increased mean fluorescence intensity (MFI).

Clinical Development Plan

We plan to explore this potential in our planned Phase 1 trial in SCLC and NETs where there is a significant need for new treatment options. We plan to
complete IND-enabling studies, linker-payload process development and submit an IND in mid-2026.

- 130 -

MATTERS FOR APPROVAL AT THE SPECIAL MEETING

PROPOSAL NO. 1:

APPROVAL OF THE DIVESTITURE PROPOSAL

THE AADI BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT AADI STOCKHOLDERS VOTE “FOR” THE APPROVAL OF THE DIVESTITURE AND THE
TRANSACTIONS CONTEMPLATED BY THE DIVESTITURE AGREEMENT.

Overview

The Divestiture is the sale by Aadi to Kaken of 100% of the outstanding shares of capital stock of Aadi Sub and thereby all or substantially all of Aadi’s
assets related to its FYARRO Business, pursuant to the terms of the Divestiture Agreement, which may be deemed to be a sale of substantially all of Aadi’s assets under Section 271 of the DGCL. We are seeking the approval of Aadi
stockholders for the Divestiture because the question of whether the Divestiture constitutes the sale of substantially